Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients with Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

Clinical Infectious Diseases

Volumn 65, Issue 1, 2017, Pages 13-19

  Feld, Jordan J ^a   Ramji, Alnoor ^b   Shafran, Stephen D ^c   Willems, Bernard ^d   Marotta, Paul ^e   Huchet, Emmanuelle ^f   Vachon, Marie Louise ^g   Svarovskaia, Evguenia S ^h   Huang, K C ^h   Hyland, Robert H ^h   Yun, Chohee ^h   Massetto, Benedetta ^h   Brainard, DIana M ^h   McHutchison, John G ^h   Tam, Edward ⁱ   Bailey, Robert ^j   Cooper, Curtis ^k   Yoshida, Eric M ^l   Greenbloom, Susan ^m   Elkhashab, Magdy ⁿ   Borgia, Sergio ^o   Swain, Mark G ^p   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b Research Institute   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f Clinique Medicale l'Actuel   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h GILEAD SCIENCES   (United States)

ⁱ LAIR Centre   (Canada)

^j GI Research   (Canada)

^k OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^l VANCOUVER GENERAL HOSPITAL   (Canada)

^m Toronto Digestive Disease Associates   (Canada)

ⁿ Toronto Liver Centre   (Canada)

^o William Osler Health System   (Canada)

^p UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

genotype 3 hepatitis C virus; NS5A; NS5B

Indexed keywords

HEMOGLOBIN; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; CANADA; CARPAL TUNNEL SYNDROME; CELLULITIS; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEART ATRIUM THROMBOSIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 3 INFECTION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPONATREMIA; INSOMNIA; INTERVERTEBRAL DISK DISEASE; IRRITABILITY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MUTATION; NAUSEA; OPEN STUDY; PERSONALITY DISORDER; PRIORITY JOURNAL; SIDE EFFECT; SUICIDAL IDEATION; SUSTAINED VIROLOGIC RESPONSE; AGED; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS C; CLINICAL TRIAL; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG RESISTANCE, VIRAL; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; URIDINE MONOPHOSPHATE;

EID: 85021845527     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix289     Document Type: Article

References (29)

1. Messina JP, Humphreys I, Flaxman A, et al Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77-87.
2. Glower E, Estes CC, Hindman S, et al Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61(suppl 1):S45-57.
3. Saraswat V, Norris S, de Knegt RJ, et al Historical epidemiology of hepatitis C virus (HCV) in select countries-volume 2. J Viral Hepat 2015; 22(suppl 1):6-25.
4. Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol 2016; 22:1684-700.
5. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011; 18:745-59.
6. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-64.
7. Bochud PY, Cai T, Overbeck K, et al; Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51:655-66.
8. van der Meer AJ, Veldt BJ, Feld JJ, et al Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-93.
9. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U. S. veterans with HCV. Hepatology 2014; 60:98-105.
10. Lawitz EJ, Gruener D, Hill JM, et al A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57:24-31.
11. Koff RS. Review article: The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39:478-87.
12. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61:56-65.
13. Gilead Sciences. Harvoni (ledipasvir and sofosbuvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences, 2016.
14. Gane EJ, Hyland RH, An D, et al Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149:1454-61. e1.
15. Ampuero J, Romero-Gomez M, Reddy KR. Review article: HCV genotype 3-the new treatment challenge. Aliment Pharmacol Ther 2014; 39:686-98.
16. Foster GR, Afdhal N, Roberts SK, et al; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-17.
17. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, treating hepatitis C. Available at: Http:www. hcvguidelines. org/. Accessed 16 August 2016.
18. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
19. Cheng G, Tian Y, Doehle B, et al In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 2016; 60:1847-53.
20. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 2016; 151:501-12. e1.
21. Lawitz E, Mangia A, Wyles D, et al Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
22. Saeed M, Andreo U, Chung HY, et al SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 2015; 524:471-5.
23. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-21.
24. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2013; 57:611-3.
25. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 2013; 57:13-8.
26. Leroy V, Angus P, Bronowicki JP, et al Daclatasvir, sofosbuvir, ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016; 63:1430-41.
27. Cheng G, Yu M, Peng B, et al GS-5816 a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier [abstract 1191]. In: 48th annual meeting of the European Association for the Study of the Liver, Amsterdam, 24-28 April 2013. J Hepatol 2013; 58:S484-5.
28. Hebner C, Gontcharova RK, Chodavarapu C, et al Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 1-3 NS5A resistance-associated variants [abstract 470]. In: 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, 1-5 November 2013. Hepatology 2013; 58:433A.
29. Gilead Sciences. Epclusa (sofosbuvir and velpatasvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences, 2016.